Accuray touts CyberKnife clinical results

Radiation therapy firm Accuray touted new clinical data, presented at the recent 14th World Conference on Lung Cancer in Amsterdam, on the company's CyberKnife robotic radiosurgery system and its TomoTherapy radiation therapy system.

The research included two studies from the Netherlands on the ability of the TomoTherapy and CyberKnife systems to deliver stereotactic body radiation therapy (SBRT) for primary lung cancer and lung metastases.

In the first study, 89 patients were treated with the TomoTherapy system at the Radiotherapeutisch Instituut Stedendriehoek en Omstreken in Deventer. Two-year local progression-free survival was 95%, suggesting that image-guided SBRT with TomoTherapy provided an effective treatment option for this group of patients, according to Accuray.

The second study, conducted at the Daniel den Hoed Cancer Center in Rotterdam, focused on the center's experience using CyberKnife to treat 56 patients with metastatic lung tumors. Twenty-four of these patients had central tumors. Researchers were able to deliver radiation doses in small fractions to achieve high rates of tumor control with low rates of side effects, regardless of tumor location, Accuray said.

The company also highlighted data from two centers in Italy: the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori and the G.B. Morgagni - L. Pierantoni Hospital. The data showed that intensity-modulated radiation therapy (IMRT) using the TomoTherapy system can provide additional treatment options for patients with advanced-stage lung cancer when combined with systemic chemotherapy, according to the firm.

Page 1 of 560
Next Page